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Abstract: Chronic inflammation and angiogenesis are associated with colonic carcinogenesis. Enteric
glia-derived S100B protein has been proposed as an “ideal bridge”, linking colonic inflammation
and cancer, given its dual ability to up-regulate nuclear factor-kappaB (NF-κB) transcription via
receptor for advanced glycation end products (RAGE) signaling and to sequestrate wild type
pro-apoptotic wild type (wt)p53. However, its pro-angiogenic effects on cancer cells are still
uninvestigated. To this aim, we evaluated the effect of exogenous S100B (0.05–5 µM) protein
alone or in the presence of S100B blocking monoclonal antibody (mAb) (1:105–1:104 v/v diluted)
on (1) cultured Caco-2 cells proliferation, migration and invasiveness in vitro, respectively by
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)-formazan, wound healing and
matrigel invasion assays and (2) its effect on the release of pro-angiogenic factors, such as vascular
endothelial growth factor (VEGF) by ELISA and immunofluorescence analyses. The effect of
S100B alone or in the presence of S100BmAb was then investigated on RAGE/pAkt/mammalian
target of rapamycin (mTOR) signaling pathway by immunoblot analysis. Our results showed that
S100B markedly increases proliferation and invasiveness of Caco-2 cells, through the release of
pro-angiogenic VEGF and NO paralleled to a significant decrease of wtp53 expression mediated
by RAGE-p38 mitogen-activated protein kinase (MAPK)/pAkt-mTOR and hypoxia-inducible factor
1-alpha (HIF1α) pathways. Such effects were counteracted by S100BmAb, indicating that S100B
targeting is a potential approach to inhibit colon carcinoma proliferation and angiogenesis.
Keywords: S100B; colorectal carcinoma; tumor microenvironment; angiogenic mediators; VEGF;
RAGE; Akt/mTOR; Caco-2 cell proliferation
1. Introduction
In addition to genetic, environmental and dietetic influences [1,2], chronic inflammatory conditions
are well-recognized risk factors for colonic carcinogenesis [3,4]. One of the consequences of chronic
colonic inflammation is neovascularization or angiogenesis, the process of formation of new blood
vessels from existing ones [5] that is intimately connected with a tumor microenvironment (TME)
setup enabling cancer cells to metastasize and migrate from the primitive tumor site [6]. It has
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been largely established that the aberrant release of different signaling molecules in the TME is
able to autocrinally perpetuate the growth and proliferation of colorectal cancer (CRC) cells and
their migration through the secretion and release of vascular endothelial growth factor (VEGF) [7].
By binding specific receptors, namely VEGF-R1 and 2, [8,9] VEGF stimulates neovascularization, and,
in turn, cancer cell invasion and metastasis, and this negatively impacts on the prognosis of nearly
30% of early-diagnosed CRC patients [10]. The mammalian target of rapamycin (mTOR) is a protein
kinase of the PI3K/Akt pathway that has been crucially involved in the activation and control of cell
proliferation, survival, migration and angiogenesis. An altered mTOR signaling pathway has been
described in many human cancers, including CRC [11,12]. Moreover, phosphorylation of mTOR leads
to a downstream increased secretion of VEGF, leading to marked angiogenesis in both neoplastic and
non-neoplastic processes [13]. Signaling molecules acting as angiogenesis promoters via the Akt/mTOR
pathway or able to perpetuate colonic inflammation might thus be regarded as bridging factors, linking
chronic inflammation to the carcinogenic drift. The identification of Akt/mTOR activators and their
targeting, thus, may be of potential interest to develop new drugs in CRC. In this context, enteric
glia-derived Ca+2/Zn+2-binding S100B protein emerges as a signaling molecule whose aberrant release
plays a key role in both colonic inflammation [14] and carcinogenesis [15], given its downstream
pro-inflammatory effects and mitogenic activity demonstrated in the gut, as well as in several highly
malignant extra-intestinal cancers, such as melanoma and glioma [16–18]. At a molecular level,
once over-secreted, S100B accumulates at the receptor for advanced glycation end products (RAGE)
site [19], causing the downstream activation of mitogen-activated protein kinase (MAPK) with the
consequent phosphorylation and activation of nuclear factor-κB (NF-κB) [20,21]. Moreover, S100B
significantly inhibits the function of wild type (wt) p53 [22], suppressing de facto, a key physiological
pro-apoptotic control of cell tumorigenesis. To date, a possible pro-angiogenic effect of S100B in colon
cancer cells and its underlying molecular mechanism(s) have not been investigated yet. Given this
background, the present research aimed at (1) evaluating the putative effects of S100B protein on cancer
cells proliferation, invasion, migration and on the release of pro-angiogenic mediators in human colon
adenocarcinoma Caco-2 cell line. We then examined S100B effects (2) on Akt/mTOR pathway and
VEGF signaling in the presence or absence of specific monoclonal anti-S100B antibody, in order to
confirm/exclude its specific involvement in CRC cells-related malignancy and angiogenesis.
2. Results
2.1. Effect of S100B on Caco-2 Cell Proliferation, Migration and Invasion In Vitro
Exogenous S100B (0.05–5µM) challenge caused a significant and concentration-dependent increase
of cultured Caco-2 cell line proliferation by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) analysis (+16%, +33%, +58% and +111%) at 48 h in comparison with vehicle-treated
(unstimulated) cells (Figure 1A). Coincubation with a monoclonal anti-S100B antibody (1:105–1:104 v/v
diluted), concentration-dependently counteracted S100B (5 µM) effect (−22% and −43%, respectively)
(Figure 1A). No significant changes were noted following S100B monoclonal antibody (mAb) (1:104 v/v
diluted) alone, while, both RAGEmAb (1:104 v/v diluted) and p39MAPK/pAkt inhibitor SB203580
(10 µM) caused a significant reduction of cell proliferation (−20% and −23%) respectively vs. S100B
5 µM group.
The wound healing assay (Figure 1B) showed a significant increase of cell migration rate in the
scratched area following incubation with S100B (0.05–5 µM), vs. the vehicle group (+25%, +84% and
+161%, respectively vs. vehicle group) (Figure 1B–D) and this effect was inhibited in the presence of
S100BmAb (1:105–1:104 v/v diluted) (Figure 1B–D), as confirmed by the observation that the distance
between the borders of the wound was concentration-dependently (−25% and −48% vs. S100B 5 µM
group) preserved. No significant effect in terms of cell migration inhibition was produced by S100BmAb
alone (1:104 v/v diluted) whereas both RAGEmAb (1:104 v/v diluted) and SB203580 (10 µM), caused a
marked decrease of cell migration rates (−26% and −29% respectively vs. S100B 5 µM).
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Figure 1. S100B stimulates Caco-2 cell proliferation, migration and invasion and its effect is blocked by
S100B monoclonal antibody (mAb). (A) 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) assay showing the effect of S100B (0.005–5 µM) in the presence or absence of S100BmAb
(1:105–1.104 v/v diluted), receptor for advanced glycation end products (RAGE)mAB (1:104 v/v diluted)
and/or SB203580 p38/pAkt inhibitor (10 µM) on Caco-2 cell proliferation rate at 48 h. (B) Wound healing
assay and (D) the relative quantification indicating a concentration-dependent inhibitory effect of
S100BmAb on cellular migration induced by S100B (0.05–5 µM). The graphs show also RAGEmAb
(1:104 v/v diluted) and/or SB203580 p38/pAkt inhibitor (10 µM) against S100B 5 µM stimulus at 48 h.
(C) Cell invasion assay and (E) the relative quantification of invading cells following S100B (0.05–5 µM)
exposure and relative inhibitory effect of S100BmAb (1:105–1:104 v/v diluted). Figures also show the
effect of RAGEmAb (1:104 v/v diluted) and SB203580 p38/pAkt inhibitor (10 µM) versus S100B 5 µM
stimulus. Results were expressed as mean ± standard error (SEM) of n = 6 experiments performed in
triplicate. * p < 0.05; ** p < 0.01 and *** p < 0.001 versus vehicle; ◦◦ p < 0.01 and ◦◦◦ p < 0.001 versus
S100B 5 µM; # p < 0.05 and § p < 0.05 respectively versus S100B 5 µM-treated cells. Scale bar: 100 µm;
Magnification 10X.
In the same experimental conditions, S100B (0.05–5 µM) incubation caused a significant and
concentration-dependent increase of cell invasion by matrigel assay (+27%, +70% and +100%,
respectively vs. vehicle group) (Figure 1C–E). In the presence of S100mAb (1:105–1:104 v/v diluted)
a marked decrease of cell invasion was observed (−33% and −44% respectively vs. S100B 5 µM),
while S100BmAb alone (1:104 v/v diluted) did not result in any significant cell invasion rate in
comparison with the vehicle group, and both RAGEmAb (1:104 v/v diluted) and SB203580 (10 µM)
respectively, caused a marked decrease of cell invasiveness versus S100B 5 µM group (−30% and
−21% respectively).
2.2. S100B Induces VEGF-R2 and Inducible Nitric Oxide-Synthase (iNOS) Protein Expression Upregulation
Causing Parallel Release of Pro-Angiogenic VEGF and NO by Cultured Caco-2 Cells
Following S100B 5 µM exposure, immunofluorescence analysis revealed that both VEGF-R1 and
VEGF-R2 protein were significantly increased (+250% and +268% respectively) in comparison with the
vehicle group (Figure 2A–C) at 24 h. In the same experimental conditions, we also observed a significant
upregulation of nuclear Ki67 protein, a marker of colonic tumor cell proliferation, as compared to
control group (+221%) (Figure 2B,C). S100BmAb (1:104 v/v diluted) caused a significant decrease of both
VEGF-R1 (−58%), VEGF-R2 (−63%) and Ki67 (−69%), vs. S100B 5 µM group (Figure 2A–C). Our data
also showed that S100B 5 µM caused a significant increase (+113%) of iNOS protein expression in
comparison to vehicle group cells (Figure 2A–C) and, once again, incubation with S100BmAb (1:104 v/v
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diluted) resulted in a concentration-dependent inhibition of iNOS protein expression (−50%), versus
S100B 5 µM (Figure 2A–C).
S100BmAb (1:104 v/v diluted) alone did not increase VEGF-R1, VEGF-R2, iNOS and Ki67 expression
in comparison with the vehicle group, while a significant decrease of all these proteins expression was
observed after coincubation with RAGEmAb (1:104 v/v diluted) or SB203580 (10 µM).
Immunofluorescence analysis revealed that S100B (0.05–5 µM) caused a significant and
concentration-dependent increase in both NO (expressed as nitrites amount) (+30%, +161%, +291%)
and VEGF (+32%, +168% and +361%) (Figure 2F,G) released by cultured Caco-2 cells. As expected,
S100BmAb (1:105–1:104 v/v diluted) caused both nitrite (−50% and −72%) and VEGF (−40% and −62%)
(Figure 2D,E) decrease in comparison to S100B 5 µM group, while no effects on both nitrite and VEGF
secretion were observed following the incubation of S100BmAb (1:104 v/v diluted) alone. On the
contrary, in the presence of both RAGEmAb (1:104 v/v diluted) and SB203580 (10 µM), the effect of
S100B 5 µM was consistently inhibited on both nitrites (−35% and −49% respectively) and VEGF
secretion (−26% and −35% respectively), further supporting the role of RAGE/p38/Akt pathway in
mediating the effects of S100B on pro-angiogenic factors.
Figure 2. Cont.
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Figure 2. S100B stimulates pro-angiogenic vascular endothelial growth factor (VEGF) and
NO release through Akt/mammalian target of rapamycin (mTOR) pathways and relative
molecular downstream regulation by S100BmAb. (A) Immunoreactive bands referred
to RAGE, phosphorylated/unphosphorylated-p38MAPK, phosphorylated/unphosphorylated Akt,
phosphorylated ERK/unphosphorylated ERK, phosphorylated/unphosphorylated-mTOR, wild type
(wt)p53, hypoxia-inducible factor 1-alpha (HIF1α) protein expression and (H) their relative densitometric
analysis (arbitrary units normalized on the expression of the housekeeping protein β-actin, showing the
effect of S100B (0.05–5 µM) in the presence of S100BmAb (1:105–1:104 v/v diluted) at 24 h, S100BmAb
alone (1:104 v/v diluted) or S100B 5 µM in the presence of, respectively RAGEmAb (1:104 v/v diluted) or
SB203580 (10 µM). (B) Immunofluorescence analysis showing inducible nitric oxide-synthase (iNOS;
green), VEGF-R1 and (C) VEGF-R2 (red) and (D) Ki67 (red) immunoreactivity with (E) the relative
quantification of iNOS (green bars), VEGF-R1 (yellow bars) VEGF-R2 (red bars) and Ki67 (blue bars)
protein expression in Caco-2 cells treated with S100B (5 µM) in presence or absence of S100BmAb
(1:104 v/v diluted), or RAGEmAb (1:104 v/v diluted) and SB203580 (10 µM). In the same experimental
conditions, (F and G) quantification of nitrite and VEGF levels respectively in the supernatant media of
Caco-2 cells exposed to the same treatment. Results were expressed as mean ± SEM of n = 6 experiments
performed in triplicate.* p < 0.05; ** p < 0.01 and *** p < 0.001 versus vehicle; ◦ p < 0.05, ◦◦ p < 0.01 and
◦◦◦ p < 0.001 versus S100B 5 µM; # p < 0.05 ## p < 0.01; § p < 0.05 and §§ p < 0.01, respectively versus
S100B 5 µM-treated cells. Scale bar: 10 µm; Magnification 10X.
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2.3. S100B Mediates a RAGE-Dependent Activation of p38/pAkt/pmTOR Signaling and Reduces wtp53
Expression in Cultured Caco-2 Cells
S100B (0.05–5 µM) challenge determined a significant increase of RAGE expression in comparison
with the vehicle group (+30%, +128% and +298% respectively); similarly the expression of
phosphorylated p38MAPK (+23%, +46% and +228%), phosphorylated-Akt (+120%, +220% and +420%),
phosphorylated ERK (+260%; +320% and +470%) and phosphorylated-mTOR (+33%, +100% and
+233%) was also significantly increased (Figure 2F,G). Our results showed that S100B/RAGE activation
were paralleled with a downstream upregulation of hypoxia-inducible factor 1-alpha (HIF1α) (+40%,
+140% and +380% vs. vehicle group respectively) (Figure 2F,G). In the same experimental conditions,
S100B caused a concentration-dependent downregulation of wtp53 vs. the vehicle group (−23%, −46%
and −79%, respectively) (Figure 2F,G). Interestingly, S100B effects were markedly counteracted by
S100BmAb (1:105–1:104 v/v diluted) incubation. In particular, we observed a concentration-dependent
decrease of RAGE (−39% and −66%), pp38 (−53% and −71%), phospho-ERK (−50% and −75%) and
pAkt/pmTOR expression (−54%, −69% and −50%, −75%), respectively vs. S100B 5 µM group and
HIF1α (−54% and −67% vs. S100B 5 µM group). This resulted in a significant increase of wtp53 protein
expression (+187% and +415% respectively vs. S100B 5 µM group). In all treatment groups, S100BmAb
alone did not result in any significant variation vs. vehicle group, while both RAGEmAb (1:104 v/v
diluted) and SB203580 were able to significantly counteract all the above-reported effects in comparison
to S100B 5 µM stimulus.
3. Discussion
A marked release of pro-angiogenic mediators is related to poor prognosis in cancer patients [23].
The identification of molecular pathways bridging chronic inflammation to a pro-angiogenic TME
setup is crucial in identifying new potential therapies for colon cancer. Previous studies showed
that the release of S100B protein, a neurotrophic protein expressed by enteric glia cells in the gut, is
commonly upregulated in various models of cancer and is often associated with tumor progression
and prognosis [22,24,25]. Here, we demonstrated that increasing concentrations of S100B protein are
accompanied by a marked increase in proliferation, migration and invasion rates in an in vitro model
of human colon cancer.
Moreover, S100B challenge also had a direct pro-angiogenic effect in vitro on HUVEC cells,
causing a significant increase of tube formation and length. This effect was, furthermore, significantly
counteracted by the coincubation with specific S100BmAb, or RAGE blocking antibody and by the
p38MAPK/Akt inhibitor, SB203580 (Figure S1).
S100B activity led to a significant increase of both VEGF and NO release from cultured cells, that
paralleled a marked upregulation of VEGF receptors 1/2 and iNOS protein expression in the same
experimental conditions. VEGF and NO are crucial components of the angiogenesis network since they
synergistically promote a pro-angiogenic milieu in the colon [26,27]. Different evidence produced by
our research group has been addressed in the attempt to clarify the role exerted by an increased S100B
level and perpetuation of chronic inflammation in the gut mucosa. In particularly, the connection
between NO and S100B has been explored and the S100B/RAGE/phospho-p38MAPK interaction has
been identified as a key signaling pathway by which S100B may stimulate a pro-inflammatory effect
in colon mucosa [14,28–30]. The importance of the RAGE receptor and the relative downstream
activation of p38/Akt pathway induced by exogenous S100B was supported by the observation that
its proliferative and pro-angiogenic effects were significantly counteracted by either RAGEmAb or
SB203580 (a synthetic p38/Akt inhibitor). In addition to this molecular pathway, here we demonstrated
that S100B can also activate the pAkt-pERK/pmTOR/HIF1α signaling pathway (Figure 3), cross-linking
the inflammatory cascade to neoangiogenesis and upregulation of VEGF and its receptors. These data
are in line with a previous report that indicated that micromolar concentrations of S100B interact at the
RAGE site and profoundly alter cell cycle and proliferation in neuronal cells, inducing pro-mitogenic
activity of pAkt [20]. Notably, the activation of the Akt/mTOR pathway is downstream associated with
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signals promoting resistance to apoptosis, altered tissue remodeling and metastasis formation [31].
The molecular interaction between p38MAPK and pAkt/pmTOR pathway have been independently
observed both in diabetic fibroblasts [32] and HeLa cells [33]. Our data are in line with previously
published studies showing the mitogenic effect of S100B proteins family [34,35]. Along this line,
Jiang et al [36] firstly described the effect of S100B protein on proliferation and invasion on human
lung adenocarcinoma cell line PC14/B. S100B protein in particular, has been reported to sequestrate
pro-apoptotic wtp53 protein, favoring tumor progression in several human cancers, i.e., melanoma,
breast cancer or glioblastoma [17,18,37]. In a previous study from our group, S100B release was strongly
increased in chronic gut inflammation, and this might, in turn, offer mechanistic insights into the
transition from chronic inflammatory conditions, such as ulcerative colitis (UC) to colorectal cancer [38].
To the best of our knowledge this is the first study demonstrating that S100B has a direct-pro-angiogenic
effect acting in vitro as a direct neovascularization promoter by the activation of a RAGE-dependent
pAkt/mTOR pathway in a human colon adenocarcinoma cell line. We also demonstrated that the
specific monoclonal anti-S100B antibody was able to counteract the above-described pro-angiogenic
and proliferative effects in a concentration-dependent manner. Although hampered by their in vitro
nature, these results support that the selective targeting of S100B protein might represent an interesting
innovative approach in colon cancer therapy. The recent introduction of VEGF blocking antibody,
bevacizumab, in the treatment of colon adenocarcinoma has significantly improved progression-free
survival in advanced colon cancer patients [39]. However, the complexity and redundancy of
converging angiogenic and proliferation pathways can promote escape mechanisms to immunotherapy,
ultimately leading to tumor progression. The possibility, of inhibiting on one hand, the release of
pro-angiogenic factors and, on the other, of promoting cell proliferation control, can be therefore of
great interest in order to synergistically target these mechanisms. Here we show that monoclonal
antibody-mediated targeting of S100B appears to also have a further protective anti-cancer effect by
markedly increasing the expression of wtp53 protein.
Figure 3. Representation of S100B effects on Caco-2 cells. (A) S100B interacts at RAGE receptors and
downstream activates p38/Akt signaling pathway leading to cell proliferation, increased release of cell
migration and angiogenesis. (B) S100B effects are blocked by specific S100BmAb, as well as, RAGE
specific antibody and p38/Akt inhibitor SB203580, leading to a significant control of angiogenesis and
cell invasion in vitro.
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Very interestingly, in the p53 KO HCT116 cell line, S100BmAb failed to inhibit cell proliferation
rates; whilst, no significant differences were observed in terms of VEGF secretion as compared to wild
type HCT116 cells and Caco-2 cell line.
Although further in vivo studies are required to confirm these in vitro preliminary results, S100B
targeting might represent a promising therapeutic approach against colon cancer. Given the key
role of S100B in mediating chronic inflammation and carcinogenesis, we strongly believe that the
selective blockade of its effects could play an innovative and prominent role in the development of
new complementary antitumor approaches that may increase therapeutic success.
4. Materials and Methods
4.1. Materials
Caco-2 cells were purchased from European Collection of Cell Cultures (ECACC, Public Health
England Porton Down, Salisbury, UK). Cell medium, substances and reagents for cell cultures were all
purchased from Sigma-Aldrich (St. Louis, MO, USA), unless stated otherwise. Instruments, reagents
and materials for Western blot analysis were obtained from Bio-Rad Laboratories (Milan, Italy).
S100B protein was from Sigma-Aldrich (St. Louis, MO, USA) and mouse monoclonal S100B
antibody (S100BmAb) was purchased from AbCam (Cambridge, UK). Mouse anti-total Akt, mouse
monoclonal anti p-ERK/ERK was from Santacruz biotechnology (DBA, Milan, Italy) rabbit monoclonal
anti-phospho-Akt (Ser473), rabbit polyclonal anti-phospho-mTOR (pSer2448), rabbit monoclonal anti
VEGF-R1 and VEGF R-2 were purchased from Cell Technology (Euroclone, Pero, Milan, Italy). Mouse
monoclonal anti RAGE antibody was from AbCam (Cambridge, UK). Rabbit polyclonal anti-total
mTOR was from Abcam (Cambridge, UK); mouse monoclonal anti-HIF1α was purchased from Sigma
Aldrich (Milan, Italy); anti-β-actin was from Santa Cruz Biotechnology (Santa Cruz, California, USA).
SB203580 was from InvivoGen (Aurogene, Rome, Italy) and polyclonal rabbit anti-mouse IgG from
Dako (Glostrup, Denmark).
4.2. Cell Culture
Caco-2 cells obtained from ECACC (Public Health England Porton Down, Salisbury, UK) were
cultured in 6-well plates in DMEM containing 10% fetal bovine serum (FBS), 1% penicillin–streptomycin,
2 mM l-glutamate and 1% non-essential amino acids to confluence. A total of 1 × 106 cells/well were
plated and incubated for 24 h. After reaching confluence, the cells were washed three times with
phosphate-buffered saline (PBS), detached with trypsin/EDTA, plated in 10 cm diameter petri dish
and allowed to adhere for 24 h. Subsequently, DMEM was replaced with fresh medium, and the
cells were treated with increasing concentrations of S100B (0.05, 0.5 and 5 µM) dissolved in ultrapure
and pyrogen-free sterile vehicle in the presence or absence of S100BmAb (1:105–1:104 v/v diluted),
respectively. In the same experimental protocol, cells were also treated with S100BmAb (1:104 v/v
diluted) alone as an internal control group and S100B 5 µM effect was also evaluated, respectively,
in the presence of RAGEmAb (1:104 v/v diluted) or SB203580 (10 µM), both with p38/pAkt synthetic
inhibitor. S100B and relative S100BmAb or RAGEmAb dilutions, as well as SB203580 concentration,
were selected according to previously study [30,40], and pilot experiments aimed at identifying the
lowest effective concentration (data not shown).
4.3. Western Blot
Caco-2 cells protein expression was evaluated by performing a Western blot analysis. Following
treatments, cells (1 × 106) were harvested, washed twice with ice-cold PBS and centrifuged at
180× g for 10 min at 4 ◦C. The cell pellet was suspended in 100 µL ice-cold hypotonic lysis buffer
(10 mM 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid, N-(2-hydroxyethyl) piperazine-N′-(2
ethanesulfonic acid) (HEPES), 1.5 mM MgCl2, 10 mM KCl, 0.5 mM phenylmethylsulphonylfluoride,
1.5 µg/mL soybean trypsin inhibitor, 7 µg/mL pepstatin A, 5 µg/mL leupeptin, 0.1 mM benzamidine
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and 0.5 mM dithiothreitol). To lyse the cells, the suspension was rapidly passed through a syringe
needle five to six times prior to centrifugation for 15min at 13,000× g to obtain the cytoplasmic fraction.
The cytosolic fraction proteins were mixed with non-reducing gel loading buffer (50 mM Tris, 10%
SDS, 10% glycerol, 2 mg bromophenol/mL) at a 1:1 ratio, boiled for 3 min and centrifuged at 10,000×
g for 10min. The protein concentration was determined using a Bradford assay, and equivalent
quantities (50 µg) of each sample were electrophoresed on a 12% discontinuous polyacrylamide minigel.
Subsequently, the proteins were transferred onto nitrocellulose membranes that had been saturated by
incubation with 2.5% non-fat dry milk in 1× PBS overnight at 4 ◦C with the following antibodies: total
Akt, phosphor-Akt, phosphor-ERK/total ERK, mTOR, phosphor-mTOR and anti-HIF1α, and β-actin
protein expression was performed on total protein fractions of homogenates. Equivalent amounts
(50 µg) of each homogenate underwent electrophoresis through a polyacrylamide minigel. Proteins
were then transferred onto nitrocellulose membrane that were saturated by incubation with 10%
non-fat dry milk in 1× PBS overnight at 4 ◦C and then incubated, according the experimental protocols
with mouse anti-total Akt (1:1000 v/v, Cell Technology, Euroclone, Pero, MI, Italy), rabbit monoclonal
anti-phospho-Akt (Ser473) (1:2000 v/v, Cell Technology, Euroclone, Pero, MI, Italy), monoclonal
phosphor-ERK (1:500 v/v), rabbit polyclonal anti-total mTOR (1:1000 Abcam, Cambridge, UK), rabbit
polyclonal anti-phospho-mTOR (pSer2448) (1:1000 v/v, Cell Technology, Euroclone, Pero, MI, Italy),
mouse monoclonal anti-HIF1α (1:500 v/v, Sigma Aldrich, MI, Italy) and mouse anti-β-actin (1:2000 v/v).
Membranes were then incubated with the specific secondary antibodies conjugated to horseradish
peroxidase (Dako, Milan, Italy). Immune complexes were revealed by enhanced chemiluminescence
detection reagents (Amersham Biosciences, Milan, Italy). Blots were analyzed by scanning densitometry
(GS-700 imaging densitometer; Bio-Rad). Results were expressed as optical density (arbitrary units;
mm2) and normalized on the expression of the housekeeping protein β-actin.
4.4. Enzyme-Linked Immunosorbent Assay for VEGF
Enzyme-linked immunosorbent assay for human VEGF (Abcam, Cambridge, UK) was carried
out with Caco-2 cell supernatant after treatments at 24 h according to the manufacturer’s protocol.
Absorbance was measured on a microtiter plate reader. VEGF levels were thus determined using the
standard curves method.
4.5. Nitric Oxide Quantification
NO was measured as nitrite (NO2−) accumulation in the homogenates derived from Caco-2 cells
treated with S100B (0.05–5 µM) in the presence or absence of S100BmAb (1:105–1:104 v/v diluted),
or S100BmAb (1:104 v/v diluted) alone, or S100B 5 µM in the presence of RAGEmAb (1:104 v/v diluted)
or SB203580 (10 µM)by a spectrophotometric assay based on the Reference [39] Griess reaction. Griess
reagent (1 % sulphanilamide in H2O plus 0.1% naphthylethylenediamine in H3PO4) was added to an
equal volume of supernatant and the absorbance was measured at 550 nm. The NO2− concentration
was thus determined using a standard curve of sodium nitrite and referred to 1 × 106 cells.
4.6. Cell Proliferation Assay
Cell proliferation was evaluated by performing a 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay [41]. In brief, Caco-2 cells (5 × 104) were plated in
96-well plates and allowed to adhere for 24 h. After that, DMEM was replaced with fresh medium,
and the cells were treated with increasing concentrations of S100B 0.005–5 µM) dissolved in ultrapure
and pyrogen-free sterile vehicle in the presence or absence of S100BmAb (1:105–1:104 v/v diluted) or
S100BmAb (1:104 v/v diluted) alone, or S100B 5 µM in the presence of RAGEmAb (1:104 v/v diluted) or
SB203580 (10 µM). After 48 h, 25 µL MTT (5 mg/mL MTT in DMEM) was added to the cells, and the
mixture was incubated for an additional 3 h at 37 ◦C. Subsequently, the cells were lysed, and the dark
blue crystals were solubilized using a 125 µL solution containing 50% N,N-dimethylformamide and 20%
(w/v) sodium dodecylsulfate (pH 4.5). The OD of each well was determined using a PerkinElmer, Inc.
Int. J. Mol. Sci. 2019, 20, 3240 12 of 15
(Waltham, MA, USA) microplate spectrophotometer equipped with a 620-nm filter. Cell proliferation
in response to treatments was calculated using the following equation: Cell proliferation at 48 h (%) =
(OD treated / OD untreated)×100.
4.7. Immunofluorescence Analysis
After the incubation with S100B (5 µM) in the presence or absence of S100BmAb (1:105–1:104 v/v
diluted), or in the presence of RAGEmAb (1:104 v/v diluted) or SB203580 (10 µM) or in the presence
of S100BmAb alone, Caco-2 cells were harvested, fixed for 30 min in 4% paraformaldehyde, washed
with ice-cold PBS and permeabilized with 0.3% Triton-X100 in PBS for 1 hour. Then, 2% bovine serum
albumin (BSA) was used to block the non-specific binding sites for 2 h. The cells were then incubated
overnight with mouse anti-VEGF-R1 (1:300 v/v) or anti-VEGF-R2 (1:200 v/v), rabbit anti-iNOS antibody
(1:100 v/v) and mouse anti Ki67 (1:100 v/v) (all Abcam, Cambridge, UK) and further incubated in the
dark for 30 min with the proper secondary antibody (fluorescein isothiocyanate (FITC)-conjugated
anti-rabbit or Texas red conjugated anti-mouse; all 1:1000 v/v, Jackson Immuno-Research, Cambridge,
UK). Nuclei were stained with Hoechst (1:50000 v/v, Thermo Fischer Scientific Inc., Waltham, MA, US).
The cells were analyzed using a microscope (Nikon Eclipse 80i, Nikon corporation, Minato, Tokyo,
Japan) and images were captured by a high-resolution digital camera (Nikon Digital Sight DS-U1,
Nikon corporation, Minato, Tokyo, Japan).
4.8. Wound Healing Assay
A wound healing assay using the Caco-2 cells was performed as described previously, with a
number of adjustments [42]. Briefly, the cells (5 × 105 cells/well) were plated on a 6-well plate and
incubated for 24 h in DMEM supplemented with 5% FBS, 2 mM glutamine, 100 U/mL penicillin and
100 µg/mL streptomycin in a humidified atmosphere of 5% CO2 and 95% air at a temperature of 37 ◦C.
The cell layer was scratched using a 200 µL sterile pipette tip; then, cells were washed with PBS three
times and untreated or incubated with S100B (0.05–5 µM) dissolved in ultrapure and pyrogen-free
sterile vehicle in the presence or absence of S100BmAb (1:105–1:104 v/v diluted) or S100BmAb (1:104 v/v
diluted) alone, or S100B 5 µM in the presence of RAGEmAb (1:104 v/v diluted) or SB203580 (10 µM).
Caco-2 cells were then washed twice with PBS and fixed with 4% paraformaldehyde for 30 min.
In order to facilitate cell counting, the nucleus of the Caco-2 cells was stained with Hoechst 33,258
(Invitrogen Life Technologies, Carlsbad, CA, USA) for 5 min at RT. The cells were subsequently washed
three times with PBS, and images were captured using a Nikon Eclipse 80 microscope equipped with a
high-resolution digital camera (Nikon Digital Sight DS-U1; Nikon Instruments, Inc.). The percentage
of migration was calculated by counting the number of cells that had migrated into scratched areas
compared with the number of cells that had remained in the peripheral areas.
4.9. Cell Invasion Assay
The cell invasion assay was assessed using the Millipore 24-well Millicell Chamber of pore size
8 mm (Millipore, Burlington, MA, USA), according to Zhao et al. [43]. Briefly, the cells (2 × 105 cells)
cells in DMEM without FBS were added into the upper chamber pre-coated with matrigel (Sigma).
DMEM supplemented with 30% FBS was in the lower chamber. After the incubation with S100B
(0.05–5 µM) in the presence or absence of S100BmAb (1:105–1:104 v/v diluted) or S100BmAb (1:104 v/v
diluted) alone, or S100B 5 µM in the presence of RAGEmAb (1:104 v/v diluted) or SB203580 (10 µM) for
24 h, the chamber was fixed and stained with 0.5% crystal violet for 30 min and the non-invading cells
were removed with cotton swabs. The number of invasive cells on the lower surface of the chamber
membrane was then counted under a microscope at a magnification of 20× in five random fields.
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4.10. Statistical Analysis
Results are expressed as the mean ± standard error (SEM) of the mean of n experiments. Statistical
analyses were performed using one-way analysis of variance, and multiple comparisons were performed
using a Bonferroni post hoc test. p < 0.05 was considered to indicate a statistically significant difference.
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/20/13/
3240/s1.
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